The concept of innovative drugs continues to rise, and Shou Tai Shen's stock price hits the daily limit.

On March 27, the concept of innovative drugs continued to rise. As of the time of writing, the stock price of Shutaishen reached the daily limit, reported at 27.76 yuan, with a turnover rate of 11.69% and a transaction amount of 1.367 billion yuan.

According to news reports, data shows that by March 21, 2026, the total package for China’s innovative drug overseas business development (BD) had reached 57.1 billion USD, with an initial payment of 3.3 billion USD and a total of 53 cases. This total package is equivalent to 41% of the entire year of 2025 and has already surpassed the level of the entire year of 2024.

A report from Southwest Securities indicates that multiple positive factors are resonating to inject momentum into the sector. At the corporate level, several companies, including Frontier Biotech and Hengrui Medicine, have recently announced major collaboration authorizations, validating the technology transformation capabilities of local innovative pharmaceutical companies. In terms of performance, companies such as Aierx and Sanofi’s Guojian have issued profit forecasts, combined with several companies in the industry clearly stating profit targets for 2026, leading to a continuous rise in the sector’s prosperity. Looking ahead to the second quarter, the excellent clinical data disclosures from international top academic conferences such as AACR, ELCC, ASCO, and EHA are expected to become important catalysts for the valuation recovery of innovative pharmaceutical companies.

As a company deeply engaged in the field of biological innovative drugs, Shutaishen focuses on infections, respiratory and critical conditions, autoimmune diseases, and neurological diseases. The company’s research pipeline covers multiple categories, including monoclonal antibodies, protein drugs, gene drugs, and chemical drugs. Among them, the Velolizumab (BDB-001) targeting moderate to severe pyogenic hidradenitis and ANCA-associated vasculitis has entered the later clinical stage; the STSA-1002 injection has made rapid progress in the indication of acute respiratory distress syndrome (ARDS); and the STSP-0601 targeting hemophilia treatment also shows good potential. In addition, the company has several research products related to neurotrophic factor (NGF) drugs, including STSA-1001 for cancer pain and the Supeixin new indication project for diabetic foot ulcers, forming an innovative matrix covering multiple disease areas.

The research and development of new drugs has never been a smooth path. From target discovery to clinical trials, every step requires continuous investment and breakthroughs. With the continuous verification of domestic innovative pharmaceutical companies’ R&D capabilities and the sustained activity in the global BD trading market, innovative pharmaceutical companies represented by Shutaishen are ushering in a historical opportunity for value reassessment.

Disclaimer: The above content is transferred from other media by this website. The relevant information is intended to convey more information and does not represent the views of this website, nor does it imply this website’s endorsement of its views or verification of its content’s authenticity. If the copyright unit or individual of the manuscript does not wish to publish on this website, they can contact us, and we will remove it immediately if deemed appropriate.

Massive information and precise interpretation can be found in the Sina Finance APP.